ATE543799T1 - Piperidinyl- und piperazinylmodulatoren von g- sekretase - Google Patents

Piperidinyl- und piperazinylmodulatoren von g- sekretase

Info

Publication number
ATE543799T1
ATE543799T1 AT08839601T AT08839601T ATE543799T1 AT E543799 T1 ATE543799 T1 AT E543799T1 AT 08839601 T AT08839601 T AT 08839601T AT 08839601 T AT08839601 T AT 08839601T AT E543799 T1 ATE543799 T1 AT E543799T1
Authority
AT
Austria
Prior art keywords
secretase
piperazinyl
piperidinyl
modulators
compounds
Prior art date
Application number
AT08839601T
Other languages
English (en)
Inventor
Chih Yung Ho
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE543799T1 publication Critical patent/ATE543799T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08839601T 2007-10-19 2008-10-15 Piperidinyl- und piperazinylmodulatoren von g- sekretase ATE543799T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98118907P 2007-10-19 2007-10-19
PCT/US2008/079905 WO2009052126A1 (en) 2007-10-19 2008-10-15 PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE

Publications (1)

Publication Number Publication Date
ATE543799T1 true ATE543799T1 (de) 2012-02-15

Family

ID=40090456

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08839601T ATE543799T1 (de) 2007-10-19 2008-10-15 Piperidinyl- und piperazinylmodulatoren von g- sekretase

Country Status (19)

Country Link
US (1) US8252935B2 (de)
EP (1) EP2212287B1 (de)
JP (1) JP5439381B2 (de)
KR (1) KR101569391B1 (de)
CN (1) CN101903347B (de)
AT (1) ATE543799T1 (de)
AU (1) AU2008312612B2 (de)
BR (1) BRPI0817433A2 (de)
CA (1) CA2702837A1 (de)
CO (1) CO6270359A2 (de)
CR (1) CR11447A (de)
EA (1) EA017119B1 (de)
ES (1) ES2378594T3 (de)
IL (1) IL205045A (de)
MX (1) MX2010004309A (de)
NI (1) NI201000064A (de)
NZ (1) NZ584716A (de)
WO (1) WO2009052126A1 (de)
ZA (1) ZA201003519B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE543799T1 (de) 2007-10-19 2012-02-15 Janssen Pharmaceutica Nv Piperidinyl- und piperazinylmodulatoren von g- sekretase
EP2212277B1 (de) 2007-10-19 2016-08-31 Janssen Pharmaceutica, N.V. Amingebundene modulatoren von y-sekretase
US8692017B2 (en) 2007-10-19 2014-04-08 Janssen Pharmaceutica, N.V. Carbon linked modulators of gamma-secretase
US20120135997A1 (en) 2009-07-17 2012-05-31 Shionogi & Co., Ltd. Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
US20120129189A1 (en) * 2009-07-17 2012-05-24 Chulan Kwon Methods of Controlling Cell Proliferation
WO2011054530A1 (en) 2009-11-05 2011-05-12 Fibrostatin, S.L. Gpbp inhibition using q2 peptidomimetics
MX2021002087A (es) 2018-09-03 2021-04-28 Hoffmann La Roche Derivados de heteroarilo biciclicos.
AU2019395774B2 (en) 2018-12-13 2024-12-12 F. Hoffmann-La Roche Ag 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of Alzheimer's disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2212287A (en) * 1938-09-13 1940-08-20 William S Stateler Milk bottle holder
BE790287A (fr) * 1971-10-28 1973-04-19 Delalande Sa Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
BE826017R (fr) 1974-03-19 1975-08-26 Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
US4252951A (en) 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
US5391817A (en) 1993-12-21 1995-02-21 Bristol-Myers Squibb Biaryl phospholipase A2 inhibitors
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5416187A (en) * 1994-04-04 1995-05-16 Eastman Chemical Company Process for the preparation of phenol-functional polyester resins
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
US20060004004A1 (en) * 2004-04-05 2006-01-05 Schering Corporation Novel gamma secretase inhibitors
WO2005110963A1 (en) * 2004-05-19 2005-11-24 Cellzome Ag (biphenyl-3-yl)-carboxylic acids and derivatives thereof and their use in therapy
ATE461926T1 (de) * 2004-06-30 2010-04-15 Schering Corp Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer
WO2006004555A1 (en) 2004-06-30 2006-01-12 Paysetter Pte Ltd System and method for facilitating transfer of physical money and/or credit
DE102004033876B4 (de) 2004-07-13 2009-01-15 Christoph Kaesbohrer Dreidimensionales Struktursystem
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
EP1650183A1 (de) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl)essigsäuren, ihre Derivate und Verwendung in der Therapie
WO2006088705A1 (en) * 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
EP1847524B1 (de) 2006-04-21 2009-10-14 Cellzome Limited Terphenylderivate zur Alzheimerbehandlung
PT1849762E (pt) 2006-04-21 2009-09-16 Cellzome Ltd Ácidos bifenilcarboxílicos substituídos e seus derivados
JP2009539881A (ja) * 2006-06-09 2009-11-19 アイコス コーポレイション Dp−2アンタゴニストとしての置換フェニル酢酸
DK2215044T3 (da) 2007-10-17 2012-11-26 Cellzome Ltd Biphenylcarboxylsyrer og derivater deraf
JP5543353B2 (ja) 2007-10-19 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ γ−セクレターゼのアミド結合調節物質
ATE543799T1 (de) 2007-10-19 2012-02-15 Janssen Pharmaceutica Nv Piperidinyl- und piperazinylmodulatoren von g- sekretase
EP2212277B1 (de) 2007-10-19 2016-08-31 Janssen Pharmaceutica, N.V. Amingebundene modulatoren von y-sekretase
EA201070497A1 (ru) 2007-10-19 2010-12-30 Янссен Фармацевтика, Н.В. Промежуточные продукты мгс
US8692017B2 (en) 2007-10-19 2014-04-08 Janssen Pharmaceutica, N.V. Carbon linked modulators of gamma-secretase
US7968725B2 (en) 2008-07-22 2011-06-28 Janssen Pharmaceutica N.V. Pyridinyl modulators of γ-secretase

Also Published As

Publication number Publication date
CN101903347B (zh) 2013-03-27
NI201000064A (es) 2010-09-13
ES2378594T8 (es) 2013-02-27
IL205045A (en) 2015-08-31
ES2378594T3 (es) 2012-04-16
CA2702837A1 (en) 2009-04-23
NZ584716A (en) 2011-12-22
AU2008312612A1 (en) 2009-04-23
ZA201003519B (en) 2012-07-25
EA017119B1 (ru) 2012-09-28
AU2008312612A8 (en) 2010-05-27
WO2009052126A1 (en) 2009-04-23
BRPI0817433A2 (pt) 2015-06-16
AU2008312612B2 (en) 2013-11-28
US8252935B2 (en) 2012-08-28
US20090105275A1 (en) 2009-04-23
KR20100083829A (ko) 2010-07-22
EP2212287B1 (de) 2012-02-01
EA201070495A1 (ru) 2010-10-29
CN101903347A (zh) 2010-12-01
AU2008312612A2 (en) 2010-07-22
KR101569391B1 (ko) 2015-11-16
EP2212287A1 (de) 2010-08-04
IL205045A0 (en) 2010-11-30
CR11447A (es) 2011-01-14
JP2011500700A (ja) 2011-01-06
MX2010004309A (es) 2010-05-03
JP5439381B2 (ja) 2014-03-12
CO6270359A2 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
IL205045A0 (en) Piperidinyl and piperazinyl modulators of ?? - secretase
CY1115789T1 (el) 2,3-διυδροβενζο[1,4]διοξιν-2-υλομεθυλο παραγωγα ως αλφα2c ανταγωνιστες για χρηση στη θεραπευτικη αγωγη παθησεων του περιφερικου και του κεντρικου νευρικου συστηματος
CY1112083T1 (el) Υποκαθιστουμενα ν-φαινυλο-διπυρρολιδινο καρβοξαμιδια και η θεραπευτικη τους χρηση
ATE534625T1 (de) Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
CO6190616A2 (es) Carboxamidas n-fenil-bipirrolidina sustituidas y su uso terapeutico
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
ATE530525T1 (de) Piperidine und verwandte verbindungen zur behandlung von demenz
EA201070496A1 (ru) УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ
EA201070494A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
DE602005015697D1 (de) Te zur behandlung von alzheimer-krankheit
EA201070497A1 (ru) Промежуточные продукты мгс
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
UY32002A (es) Piridinilo moduladores de gamma-secretasa
EA201070498A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
EA200701815A1 (ru) 6-гетероарил-1,2,3,4,4а,10в-гексагидрофенантридины в качестве pde-4 ингибиторов для лечения воспалительных заболеваний
ATE502947T1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren